IN8bio

<!-- Name:DistributionId Value:8841106 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta T cell therapies biopharmaceutical company today announced that Company executives will be presenting at the following events: BIO CEO…

First cohort dosing completed in Phase 1 clinical trials of INB-200 and INB-100Data presentations made at ASCO and AACR$40M initial public offering (IPO) in August 2021 to fund continuing operations NEW YORK, Sept. 10, 2021 (GLOBE…